Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shionogi & Co ( (JP:4507) ) has provided an update.
Shionogi & Co., Ltd. has announced a merger with its wholly owned subsidiary, Shionogi Pharma Co., Ltd., effective April 1, 2027. This strategic move aims to enhance the company’s production and supply chain resilience in response to changing geopolitical and regulatory environments, particularly in the infectious disease sector.
The most recent analyst rating on (JP:4507) stock is a Buy with a Yen2770.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
More about Shionogi & Co
Shionogi & Co., Ltd. is a pharmaceutical company based in Osaka, Japan, primarily engaged in the research, development, manufacturing, and sales of prescription pharmaceuticals. The company is focused on expanding its global presence, particularly in the field of infectious disease products.
YTD Price Performance: 13.08%
Average Trading Volume: 2,301,334
Technical Sentiment Signal: Buy
Current Market Cap: Yen2148.7B
For detailed information about 4507 stock, go to TipRanks’ Stock Analysis page.